ASH 2014:血压访视间变异性增大可增加冠心病、卒中、心力衰竭及全因死亡风险

2014-05-21 国际循环 国际循环

既往研究显示,血压访视间变异性(VVV)增大会增加特定人群卒中、冠心病(CHD)及全因死亡风险,但其对一般人群上述结局及心力衰竭的影响则尚不确定。 研究者美国阿拉巴马大学伯明翰分校的Paul Muntner等人对降压和降脂治疗预防心脏病发作试验(ALLHAT)的24 004例受试者进行中位4.9年的随访,以评估收缩压及舒张压VVV与致死性CHD、非致死性心肌梗死、全因死亡率、卒中及心力衰竭的相关

既往研究显示,血压访视间变异性(VVV)增大会增加特定人群卒中、冠心病(CHD)及全因死亡风险,但其对一般人群上述结局及心力衰竭的影响则尚不确定。

研究者美国阿拉巴马大学伯明翰分校的Paul Muntner等人对降压和降脂治疗预防心脏病发作试验(ALLHAT)的24 004例受试者进行中位4.9年的随访,以评估收缩压及舒张压VVV与致死性CHD、非致死性心肌梗死、全因死亡率、卒中及心力衰竭的相关性。结果显示,以收缩压的标准差(SD)来定义VVV时,收缩压VVV增大可增加各研究结局的发生风险。校正包括平均收缩压在内的多种变量后,与最低五分位距组相比,收缩压VVV最高五分位距组受试者发生致死性CHD或非致死性心肌梗死、卒中、心力衰竭及全因死亡的风险比HR分别为1.37(95%CI:1.10~1.70)、1.45(95%CI:1.05~2.00)、1.36(95%CI:1.05~1.75)和1.65(95%CI:1.39~1.96)。采用独立于均数的SD(SDIM)及平均实际变异性(ARV)定义收缩压的VVV所获得的相关性结果与上述结果相一致。此外,舒张压VVV增大也会显著增加致死性CHD或非致死性心肌梗死、卒中、心力衰竭及全因死亡的发生风险。

综上可见,血压VVV的增大可增加心血管事件及全因死亡的发生风险,亟需开展进一步研究探寻降低血压VVV有效方法并确定降低血压VVV能否独立降低CVD风险。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1648856, encodeId=73561648856e5, content=<a href='/topic/show?id=93c329333df' target=_blank style='color:#2F92EE;'>#全因死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29333, encryptionId=93c329333df, topicName=全因死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd6423693740, createdName=lxg959, createdTime=Wed Aug 06 20:07:00 CST 2014, time=2014-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255481, encodeId=67411255481cb, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri May 23 02:07:00 CST 2014, time=2014-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301112, encodeId=8ecc13011124e, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2852, encryptionId=38e32852fe, topicName=ASH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Fri May 23 02:07:00 CST 2014, time=2014-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342300, encodeId=016d134230095, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Fri May 23 02:07:00 CST 2014, time=2014-05-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1648856, encodeId=73561648856e5, content=<a href='/topic/show?id=93c329333df' target=_blank style='color:#2F92EE;'>#全因死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29333, encryptionId=93c329333df, topicName=全因死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd6423693740, createdName=lxg959, createdTime=Wed Aug 06 20:07:00 CST 2014, time=2014-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255481, encodeId=67411255481cb, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri May 23 02:07:00 CST 2014, time=2014-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301112, encodeId=8ecc13011124e, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2852, encryptionId=38e32852fe, topicName=ASH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Fri May 23 02:07:00 CST 2014, time=2014-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342300, encodeId=016d134230095, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Fri May 23 02:07:00 CST 2014, time=2014-05-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1648856, encodeId=73561648856e5, content=<a href='/topic/show?id=93c329333df' target=_blank style='color:#2F92EE;'>#全因死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29333, encryptionId=93c329333df, topicName=全因死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd6423693740, createdName=lxg959, createdTime=Wed Aug 06 20:07:00 CST 2014, time=2014-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255481, encodeId=67411255481cb, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri May 23 02:07:00 CST 2014, time=2014-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301112, encodeId=8ecc13011124e, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2852, encryptionId=38e32852fe, topicName=ASH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Fri May 23 02:07:00 CST 2014, time=2014-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342300, encodeId=016d134230095, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Fri May 23 02:07:00 CST 2014, time=2014-05-23, status=1, ipAttribution=)]
    2014-05-23 kksonne
  4. [GetPortalCommentsPageByObjectIdResponse(id=1648856, encodeId=73561648856e5, content=<a href='/topic/show?id=93c329333df' target=_blank style='color:#2F92EE;'>#全因死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29333, encryptionId=93c329333df, topicName=全因死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd6423693740, createdName=lxg959, createdTime=Wed Aug 06 20:07:00 CST 2014, time=2014-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255481, encodeId=67411255481cb, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri May 23 02:07:00 CST 2014, time=2014-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301112, encodeId=8ecc13011124e, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2852, encryptionId=38e32852fe, topicName=ASH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Fri May 23 02:07:00 CST 2014, time=2014-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342300, encodeId=016d134230095, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Fri May 23 02:07:00 CST 2014, time=2014-05-23, status=1, ipAttribution=)]

相关资讯

第53届ASH年会 AML临床研究新近进展

  急性髓细胞白血病(AML)是每年美国血液病学会(ASH)年会最主要的部分。2011年ASH年会共有887篇有关AML的论文,其中临床试验方面的论文257篇(口头发言96篇),诊断方面的论文301篇(口头发言78篇),机制研究方面的论文191篇(口头发言65篇)。本文将就AML治疗方面一些主要亮点研究作一分析,介绍给国内医生。   AML化疗方案的优化   AML标准的化疗方案对于55岁以下